drugset / Trial / NCT06245941

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

NCT06245941

Phase 1/2 Terminated 21 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedSingle-groupOpen-labelTreatment

Summary

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.

Timeline

Start
2024-05-13
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ05105 Small molecule Oral
Background TQB3909 Unknown Oral

Indications